#36 – Eric Chehab, M.D.: Extending healthspan and preserving quality of life

Chehab's OrthoHealth program addresses weight through the full integrative stack: sleep, stress, nutrition, and exercise efficiency — not just caloric restriction. The key insight is that many orthopedic patients are systemically unwell (BMI 35+, poor sleep, high stress) and treating the knee in isolation while ignoring the metabolic environment fails. Exercise efficiency is emphasized because these patients often exercise with excessive volume and poor form, hurting rather than helping their joints.

Chehab's clinical communication: tell patients upfront that most meniscal and shoulder complaints will improve with time and PT. Set the 4-8 week expectation at the first visit. Check back in and adjust if no improvement. This framing prevents patients from feeling abandoned while also preventing premature surgery. The PREASE misread — that surgery is never needed — is just as harmful as the overcorrection toward always operating.

Chehab frames this through what cannot be recovered rather than what can: you cannot go back to your age-30 bone density if you were sedentary in your 20s. Hormone therapy in postmenopausal women can slow the decline (estrogen is anti-osteoclastic), but cannot fully replace the structural stimulus of loading. The bone stimulator technology (electromagnetic fields) is promising for fracture healing but not yet safe or practical for population-level osteoporosis prevention due to theoretical cancer-stimulation risk.

Chehab draws the threshold graph in clinic: above the line = pain and swelling, below = comfort. The 45-year-old former marathoner who can no longer run is typically operating above threshold at running pace but well below threshold at walking and cycling. The critical clinical job is to prevent them from concluding they cannot exercise when the accurate statement is they cannot run, but they can swim, bike, and strength train. Abandoning exercise entirely to avoid crossing the threshold is the worst possible outcome — it ensures rapid deconditioning and a far lower threshold by age 65.

Chehab is explicit that online ratings do not capture what patients actually need: they capture negative outliers who are angry and positive outliers who are effusive, missing the large average population. Tom Brady being drafted in the sixth round of the NFL despite every measurable athletic metric is his analogy for why surgical outcome metrics are hard to design and easy to game. The most reliable signal Chehab knows is word-of-mouth within the medical community — who do other orthopods send their families to?

Chehab's broader point is that trainers in most commercial gyms are young individuals who lift weights well but lack clinical understanding of joint biomechanics. The solution is not avoiding squats and lunges — both are enormously valuable exercises — but learning the correct mechanics, which are counterintuitive: in a lunge, the back leg and posterior chain do the work, and the front leg is essentially along for the ride. Getting this wrong under repeated loading is the mechanism for most patellofemoral pain syndrome seen in gym-goers.

Chehab's example: the 45-year-old who ran marathons, now cannot even run a 5K with her daughter without unbearable pain. Rather than prescribing stop running, the correct frame is: here is what you can still do at full intensity — swimming, biking, weights. And here is why doing those aggressively now will mean you are in a completely different place at 65 than if you had stopped everything. The menopause accelerant Attia adds: a sedentary 45-year-old who hits perimenopause at 50 faces a double deceleration of musculoskeletal capacity — the joint arthritis plus the hormonal loss of bone density and muscle mass.

Attia shares his own experience: his year of back recovery from the L5-S1 free fragment taught him to squat to pick up anything from the floor, sneeze with his core braced, brace over the counter before bending forward at the sink. For the shoulder, Chehab's personal adaptation: never do a dead-hang pull-up without first engaging scapular retraction; avoid all overhead pressing; use static overhead holds rather than dynamic pressing.

Chehab's clinical team developed the OrthoHealth program drawing on Attia's general longevity framework — addressing sleep, stress, diet, and exercise efficiency together rather than just prescribing weight loss. The program targets patients who are over BMI 30 with multiple comorbidities; for these patients weight loss is not just about the knee, it's about reversing the metabolic environment that accelerates joint degeneration. The 4-pound figure comes from biomechanical engineering models of how the center of gravity of the upper body applies torque to the tibio-femoral joint. The same multiplier phenomenon exists in the spine and hip.

Chehab notes that bisphosphonates slow osteoclastic resorption and improve DEXA T-scores, but the bone deposited under bisphosphonate treatment may not be as well-organized along stress lines as load-driven bone — leading to atypical femur fractures (tension-sided failure) with prolonged use. The pharmacological pipeline is focused predominantly on osteoclast inhibition rather than osteoblast stimulation. Bone stimulators (electromagnetic fields) can promote osteoblastic activity for fracture healing but carry cancer-stimulation concerns that prevent broader application. The evolutionary 'why' for this age-30 inflection point is unknown — Chehab acknowledges it as a genuinely unresolved question in bone biology.

The paradox: if patients are unblinded to the sham, you lose the placebo benefit — so you cannot actually offer the ethically correct treatment. The post-operative care itself (sling immobilization, mandatory PT, reduced physical loading) may be what heals the shoulder, not the procedure. Chehab still does subacromial decompressions, acknowledging the science but noting the absolute improvement levels in both arms were real and substantial. The analogy to meniscectomy literature is exact: the PREASE 2016 paper likewise showed no superiority of surgery over PT for degenerative meniscal tears, but the correct interpretation is try conservative first, not surgery never works.

The PREASE 2016 New England Journal paper compared PT versus arthroscopic partial meniscectomy for degenerative tears in 40-50 year olds. The surgery arm showed no benefit over PT, but this was misread by some critics as meniscus surgery is never warranted. The correct clinical message is start conservative, cross to surgery only in true failures. Mechanical tears (locked knee, inability to fully extend, recurrent effusion unresponsive to PT) still warrant intervention. The key framing from Chehab: on MRI, 80-90% of knees in adults over 40 show meniscal signal change — MRI findings alone should never be the operative indication.

Chehab rates PRP at 3 out of 10 on a dialing-in scale. He identifies the path to improvement: standardize preparation protocols, identify the patient subgroups most likely to respond (likely specific tendinopathies, not osteoarthritis), and run properly powered head-to-head RCTs. The placebo issue is thorny — a saline injection into a tendon delivers some local effect; a centrifuge-derived growth factor injection delivers more. Disentangling those layers requires an active-placebo comparator that does not yet exist. He is more skeptical of intra-articular PRP for osteoarthritis than for tendinopathy, where the mechanism is at least biologically plausible.

Chehab draws a clear contrast: in sports medicine, taking a patient from 80% to 100% involves a small improvement margin and the downside is typically back to baseline. In spine, taking someone from 70% toward 90% carries genuine risk of landing them at 20%. The cases where spine surgery is unambiguously warranted are neurological compromise (spinal cord signal change on MRI, motor weakness, cauda equina syndrome, myelopathy) where inaction carries worse risk. Nick's cervical disc with spinal cord signal change (myelomalacia) is presented as a clear operate-now case — the downside of waiting was paralysis.

Chehab draws a graph for these patients: there is a threshold above which activity causes pain and swelling, and below which the joint is symptom-free. The goal is to stay active right up against that threshold — to modulate it upward through strengthening and weight loss, not to be forced below it by abandoning exercise. The coping framework here is central: accept the new ceiling, maximize what you can do within it, let the joint (not fear) set the limit. The catastrophic outcome he wants to prevent is the 45-year-old runner who stops all activity because running is impossible, and becomes sedentary — thereby ensuring that by 65 they are far worse off than if they had pivoted to swimming or cycling.

Chehab's framework for evaluating these procedures mirrors drug development: phase one (safety), phase two (efficacy), phase three (effectiveness). He believes the promise is real — stem cells may genuinely modulate cartilage degeneration — but the rigor is absent. His pragmatic advice: direct interested patients to academic medical centers running formal trials. They may receive placebo, they may receive stem cells, but they will not pay $13,000 and they will generate evidence. The larger placebo effect of more invasive procedures is a real confound — the more elaborate the extraction (bone marrow biopsy from posterior iliac crest, fat aspiration, etc.), the larger the placebo response independent of any biologic mechanism.